Abstract
Kelly Valla, PharmD, BCOP, of Winship Cancer Institute of Emory University, describes the clinical implications of novel agents for aggressive B-cell lymphoma, which were described at a session presented by Gilles Salles, MD, PhD, of Memorial Sloan Kettering Cancer Center, at the 2021 SOHO Annual Meeting.
